News | February 06, 2013

Researchers Gather to Discuss Therapy Alternative for Breast Cancer Research

Proton therapy evaluated as a treatment option

 

February 6, 2013 — Radiation oncologists from some of the country’s leading cancer centers will meet in Phoenix to discuss the appropriate use of proton beam therapy in the treatment of breast cancer. Proton therapy is a highly precise form of radiation currently being used to treat a number of cancers and non-cancerous tumors.

Recent studies have reported that long-term side effects from standard radiation therapy for breast cancer can include damage to the heart and lungs, particularly in cases where the left breast is involved and radiation treatments “bathe” these vital organs. In many cases, the side effects do not emerge until 10 years or more after treatment.

Proton therapy is ionizing (high-energy) radiation and has the same destructive mechanism in attacking cancer cells as X-ray radiation, but because of its precision, protons are able to provide higher doses of radiation energy to tumors without increasing rates of side effects.

“We now know that breast cancer patients treated with standard radiation have a risk of developing secondary side effects,” said Eugen Hug, ProCure’s chief medical officer. “That is why it is important for us as a medical community to come together and discuss new therapies and treatment options that can be equally as effective, but spare the long-term damage.”

The two-day conference, to be held at The Arizona Biltmore Feb. 8-9, is being sponsored by ProCure Treatment Centers Inc., and is drawing in over 35 researchers from around the country.

Proton therapy is most often used to treat tumors of the brain, central nervous system, head and neck, lung and prostate, as well as sarcomas and many pediatric cancers. Its precision makes it especially effective for treating children and adults with anatomically complex tumors such as base of skull and tumors along the spinal cord.

Clinical trials are currently under way to evaluate the effectiveness of proton therapy for breast cancer. Physicians at ProCure Centers in Oklahoma City, Warrenville, Ill., and Somerset, N.J., will be opening two trials within the coming months to study proton therapy for women with breast tumors who would be at a high risk for heart and lung side effects. One trial will study women with advanced breast tumors while another will study proton therapy for women with early stage tumors. Additional trials are being developed.

“Proton therapy may not be the right treatment option for everyone with breast cancer, which is why discussions like these and clinical trials are important to help physicians determine which patients can be treated most effectively with maximum long-term benefit,” Hug said. “Providing patients with the best possible treatment options is our priority.”

For more information: www.procure.com

Related Content

Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Massachusetts Superior Court Grants Hologic Preliminary Injunction in Trade Secrets Lawsuits
News | Mammography | December 12, 2018
December 12, 2018 — A Massachusetts Superior Court granted a preliminary injunction in lawsuits by Hologic against Ch
Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...